Enabling Policy Planning and Innovation Management through Patent Information and Co-Authorship Network Analyses: A Study of Tuberculosis in Brazil

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Vasconcellos, Alexandre Guimarães ^a   Morel, Carlos Medicis ^b  

^a National Institute of Industrial Property INPI   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; AUTHOR; BRAZIL; CLASSIFICATION; DATA BASE; GOVERNMENT REGULATION; HEALTH CARE INDUSTRY; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; INFORMATION RETRIEVAL; MEDICAL LITERATURE; MEDICAL RESEARCH; PATENT; PATIENT INFORMATION; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; PUBLICATION; TUBERCULOSIS; UNIVERSITY; WRITING;

AUTHORSHIP; BRAZIL; DRUG INDUSTRY; HUMANS; INTELLECTUAL PROPERTY; INVENTIONS; PATENTS AS TOPIC; PERIODICALS AS TOPIC; PUBLIC POLICY; TUBERCULOSIS;

EID: 84867054772     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045569     Document Type: Article

References (33)

1. DiMasi JA, Hansen RW, Grabowski HG, (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics 22: 151-185.
2. Gadelha CAG, Maldonado JMSDV (2008) O papel da inovação na indústria farmacêutica: uma janela de oportunidad no âmbito do Complexo Industrial da Saúde. In: Buss PM, Carvalheiro JR, Romero Casas CP (orgs.) Medicamentos no Brasil: inovação e acesso, Rio de Janeiro: Editora Fiocruz.
3. Adams CP, Brantner VV, (2010) Spending on new drug development1. Health Economics 19: 130-141.
4. Light DW, Lexchin JR, (2012) Pharmaceutical research and development: what do we get for all that money? BMJ 345: e4348-e4348.
5. Morel CM (2003) Neglected diseases: under-funded research and inadequate health interventions. can we change this reality? EMBO Reports 4 Spec No: S35-S38.
6. Vasconcellos AG (2009) Como colocar a biodiversidade brasileira a serviço do desenvolvimento sociocultural e econômico do nosso Brasil? In: 60 Congresso Nacional de Botânica. Livro Eletronico (DVD) ISSN 2175-5043, São Paulo: Sociedade Brasileira de Botânica. 1072-1077.
7. dos Santos e Souza Frickmann F, Vasconcellos AG, (2011) Research and Patent of Phytotherapeutic and Phytocosmetic Products in the Brazilian Amazon. Journal of Technology Management & Innovation 6: 136-149.
8. World Health Organization (2010). Tuberculosis. fact sheet n 104. http://www.who.int/mediacentre/factsheets/fs104/en/index.html. Available: http://www.who. int/mediacentre/factsheets/fs104/en/index.html. Accessed 2012 August 31.
9. World Health Organization (2011). Global tuberculosis control 2011. http://www.who.int/tb/publications/global report/en/. Available: http://www.who.int/tb/ publications/global_report/en/. Accessed 2012 August 31.
10. Ministério da Saúde (2011). Situação da tuberculose no Brasil. Available: http://portal.saude.gov. br/portal/arquivos/pdf/apres_padrao_pnct_2011.pdf. Accessed 2012 August 29.
11. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C, (2011) Totally drug-resistant tuberculosis in India. Clinical Infectious Diseases 54: 579-581.
12. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X, (2010) Global tuberculosis drug development pipeline: the need and the reality. The Lancet 375: 2100-2109.
13. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, et al. (2012) 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxioxacin combinations: a randomised trial. The Lancet Published online July 23, 2012. Available: http://dx.doi.org/10.1016/S0140-6736(12) 61080-0.
14. de Brito Bahruth E (2004) Prospecção Tecnológica na Priorização de Atividades de C&T: Caso QTROP-TB. Doctoral thesis, Federal University of Rio de Janeiro, Faculty of Chemistry, Rio de Janeiro.
15. OECD, Eurostat (2005) Oslo Manual. GUIDELINES FOR COLLECTING AND INTERPRETING INNOVATION DATA. Paris: OECD Publishing, third edition.URL http://epp.eurostat. ec.europa.eu/cache/ITY_PUBLIC/OSLO/EN/OSLO-EN.PDF. Accessed 2012 August 30.
16. Newman ME, (2001) The structure of scientific collaboration networks. Proceedings of the National Academy of Sciences of the United States of America 98: 404-409.
17. Newman ME, (2004) Coauthorship networks and patterns of scientific collaboration. Proceedings of the National Academy of Sciences of the United States of America 101 (Suppl 1) (): 5200-5205.
18. Guimerà R, Uzzi B, Spiro J, Amaral LA, (2005) Team assembly mechanisms determine collaboration network structure and team performance. Science 308: 697-702.
19. Morel CM, Serruya SJ, Penna GO, Guimarães R, (2009) Co-authorship network analysis: A powerful tool for strategic planning of research, development and capacity building programs on neglected diseases. PLoS Neglected Tropical Diseases 3: e501.
20. Scott JP (2000) Social Network Analysis: A Handbook. SAGE Publications.
21. Newman M (2010) Networks: An Introduction. Oxford University Press, USA, 1 edition.
22. Bound K (2008) Brazil: The natural knowledge economy. Magdalen House, 136 Tooley Street, London, SE1 2TU, UK: Demos, 164 pp. Available: http://www.demos.co.uk/publications/brazil.
23. Ministério do Desenvolvimento, Indústria e Comércio Exterior Política de Desenvolvimento Produtivo (PDP). Quadro de Metas- País. Technical report. Available: http://www.mdic.gov.br/pdp/index.php/sitio/conteudo/index/3. Accessed 2012 August 29.
24. Gadelha CAG, (2003) The health industrial complex and the need of a dynamic approach on health economics. Ciência & Saúde Coletiva 8: 521-535.
25. Gadelha CAG (2006) Development, health-industrial complex and industrial policy. Revista de Saúde Pública 40 (Special issue): 11-23.
26. Morel CM, Carvalheiro JR, Romero CNP, Costa EA, Buss PM, (2007) The road to recovery. Nature 449: 180-182.
27. Esteves B, (2011) Hopes build that new infrastructure can aid drug discovery. Nat Med 17: 1174-1175.
28. Allarakhia M, Ajuwon L (2012) Understanding and creating value from open source drug discovery for neglected tropical diseases. Expert Opinion on Drug Discovery: 1-15.
29. Bhardwaj A, Scaria V, Raghava GPS, Lynn AM, Chandra N, et al. (2011) Open source drug discovery-a new paradigm of collaborative research in tuberculosis drug development. Tuberculosis (Edinburgh, Scotland) 91: 479-486.
30. Mondal R, Jain A, (2007) Extensively Drug-Resistant mycobacterium tuberculosis, india. Emerging Infectious Diseases 13: 1429-1431.
31. Brito R, Mello F, Andrade M, Oliveira H, Costa W, et al. (2010) Drug-resistant tuberculosis in six hospitals in Rio de Janeiro, Brazil. The International Journal of Tuberculosis and Lung Disease 14: 24-33.
32. Analytic Technologies (1999). Ucinet 5.0 version 1.00 [computer program]. version 6.205 natick.
33. World Intellectual Property Organization. Frequently asked questions about the international patent classification (IPC). Available: http://www.wipo.int/classifications/ipc/en/faq/. Accessed 2012 August 29.